Business ❯ Pharmaceutical Industry

Research and Development

Clinical Trials Innovation Clinical Research Cost Reduction Investment Partnerships Collaboration Market Trends Collaborations Health Innovations Regulatory Compliance Drug Discovery Strategic Decisions Intellectual Property Drug Competition Product Launch Innovative Methods Corporate Expansion Technology Transfer Investment Trends Sanofi Malaria Treatments Product Development Market Strategy Investment in Health Healthcare Innovation Clinical Development Biopharmaceuticals Innovative Drugs Funding for Health Investment Strategies Market Approval AI Integration AI in Medicine Innovation in Healthcare Contractual Relationships Biopharma

Claude AI Designed Lab‑Confirmed Protein Binders for 14 of 15 Disease Targets

Lab builds confirmed about 27% of Claude's de novo designs bound, suggesting early drug discovery is now limited by compute and wet‑lab throughput.

Bristol Myers Squibb Buys Second NVIDIA DGX SuperPOD Built on Vera Rubin

C-BRAIN Releases Open‑Source AI Toolbox to Speed Alzheimer’s Research

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

EU Drug Panel Backs Sanofi’s Cenrifki for Non‑Relapsing SPMS

OpenAI Launches GPT-Rosalind, a Biology-Tuned AI for Drug Discovery

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Sanofi’s Venglustat Notches Gaucher Type 3 Phase 3 Win, Misses Fabry Pain Endpoint

FDA Issues Draft Guidance Easing Primate Tests for Some Antibody Drugs

First New Antimalarial in Decades Tops 97% Cure in Phase III as Novartis Seeks Approval